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ABSTRACT
Objective To assess the impact of direct to consumer
advertising of prescription drugs in the United States on
Canadian prescribing rates for three heavily marketed
drugs—etanercept, mometasone, and tegaserod.
Design Controlled quasi-experimental study using
interrupted time series analysis.
Population Representative sample of 2700 Canadian
pharmacies and prescription data from 50 US Medicaid
programmes.
Main outcome measures Differences in number of filled
prescriptions per 10000 population per month between
EnglishspeakingandFrenchspeaking(control)Canadian
provinces before and after the start of direct to consumer
advertising in the United States.
Results Spending on direct to consumer advertising for
study drugs ranged from $194m to $314m (£104m-
£169m; €131m-€212m) over the study period.
Prescriptionratesforetanerceptandmometasonedidnot
increase in English speaking provinces relative to French
speaking controls after the start of direct to consumer
advertising. In contrast, tegaserod prescriptions
increased 42% (0.56 prescriptions/10000 residents,
95%confidenceinterval0.37to0.76)inEnglishspeaking
provinces immediately after the start of US direct to
consumer advertising. Uncontrolled analysis of US
Medicaiddatashowedalarger56%increaseintegaserod
prescriptions. However, this increase did not persist over
time in either country, despite continued advertising.
Conclusions Exposure to US direct to consumer
advertising transiently influenced both Canadian and US
prescribing rates for tegaserod, a drug later withdrawn
owingtosafetyconcerns.Theimpactofdirecttoconsumer
advertising on drug use seems to be highly variable and
probablydependsonthecharacteristicsoftheadvertised
drug, the level of exposure to direct to consumer
advertising, and the cultural context.
INTRODUCTION
Direct to consumer advertising is a major component
ofdrugpromotionintheUnitedStates;manufacturers
spentanestimated$4.24bn(£2.28bn;€2.88bn)in2005
—a 330% increase since 1996.
1 The merits of direct to
consumer advertising have been extensively debated,
w h i c hh a sl e dt od i f f e r i n gr e g u l a t i o n sa c r o s s
countries.
23Regulatory disputes continue worldwide,
withongoingdebateabouttheintroductionofdirectto
consumer advertising in the European Union and
Canada; at the same time, the US Senate has recently
considered legislation prohibiting such advertising
during the first two years after the release of a new
drug.
4-6 Although the debate includes a broad range of
concerns, many assertions assume that direct to
consumer advertising increases the use of particular
types of drugs. For example, proponents argue that it
increases use of effective treatments for undertreated
conditions, such as depression.
2 Opponents, however,
suggest that it drives up demand for newer drugs with
higher costs, marginal benefits, and unknown safety
profiles.
3
Both sides of the argument assume that direct to
consumer advertising increases use. However, the
effectiveness of drug advertising campaigns is unclear
and no extant studies use a concurrent control group
and quantify the impact on use of marketed drugs.
78
Previousuncontrolledlongitudinalstudieshave found
thatexpenditureondirecttoconsumeradvertisingwas
associated with higher sales of antidepressants, proton
pump inhibitors, antihistamines, and nasal sprays but
non-significant or very small association with sales of
statins and cyclo-oxygenase-2 selective non-steroidal
anti-inflammatory drugs.
9-12 How these associations
might be confounded by selection bias is unclear from
thesepreviousstudies.Forexample,drugswithalarger
pool of potential users or that are more innovative are
more likely to be promoted through both direct to
consumer advertising and physician directed cam-
paignsusingdetailing,journaladvertisements,andfree
samples.
13 Moreover, previous studies have not con-
trolled for pre-advertising trends in use or evaluated
comparable markets that are unexposed to such
advertising.
In the absence of firm evidence describing the effect
ofdirecttoconsumeradvertisingonuseofprescription
drugs, policy makers in the United States and New
Zealand have permitted it whereas their counterparts
in Europe, Canada, and Australia have prohibited it.
Theextentofbenefitsorharmsattributabletodirectto
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howeffectivelyit increasesuse ofparticular advertised
drugs and at what cost. We studied the impact of US
directtoconsumeradvertisingcampaignsonCanadian
prescribing rates for three heavily marketed drugs by
using a controlled longitudinal study design. Because
Canadians are regularly exposed to “illicit” English
language direct to consumer advertising from the
United States, we hypothesised that these campaigns
would increase use of the marketed drugs in English
speaking Canadian provinces. For any campaigns
associatedwithincreaseduseinourCanadiananalysis,
we examined US Medicaid data without a control
group to investigate whether the effects were greater
with increased exposure to direct to consumer
advertising.
METHODS
Study setting
Examination of US data alone to delineate the impact
of direct to consumer advertising is limited by two
factors. Firstly, near universal exposure to advertising
makes it almost impossible to find a comparable
unexposed control group within the United States.
14
Secondly, manufacturers start many direct to consu-
meradvertisingcampaignsshortlyafterthelaunchofa
drug—precisely when detailing to physicians and
coverage in the medical literature are likely to be at
theirhighest.Wesoughttolimitthesethreatstovalidity
by examining the impact of US direct to consumer
advertising campaigns on Canadian patterns of drug
useinprovinceswithandwithoutsubstantialexposure
to such advertising—that is, in predominantly English
speaking provinces compared with predominantly
French speaking Quebec. For drugs for which we
found an impact on Canadian prescribing rates, we
used data from nationwide US Medicaid programmes
to assess whether a dose-response relation might exist
between greater exposure to direct to consumer
advertising in the United States and more marked
increases in drug use.
Although Canada prohibits direct to consumer
advertising that includes both a brand name and
indications, substantial cross border exposure to US
advertising occurs through cable and satellite televi-
sion, radio, print media, and internet advertising.
15
Statistics Canada estimates that around 30% of televi-
sionwatchedbyEnglishspeakingCanadiansisforeign
sourced, most of which is probably US cable and
satellite stations.
16 Previous Canadian survey work
suggested that more than 85% of English speaking
patients had seen drug advertisements in the previous
year and half had seen advertisements for six or more
different products.
15 Moreover, their primary care
physicians filled nearly three quarters of patients’
requests for specific drugs.
15 Thus, English speaking
Canadians are regularly exposed to considerable
amounts of US advertising and have the means to
obtain advertised drugs.
Data sources
Ourprimaryanalysisusedmonthlydrugusedatafrom
the nationally representative CompuScript audit from
IMS Health Canada, an independent health informa-
tion company, from January 2002 to December 2006.
This audit uses a panel of approximately 2700
pharmacies (roughly 34% of all community pharma-
cies in Canada) to estimate total Canadian use of each
drug.Themajoroutcomeofinterestwasthenumberof
dispensed prescriptions of each drug per 10000
residents per month. To calculate these rates, we used
populationestimatesfromStatisticsCanada.
17Wealso
obtained IMS Health Canada data estimating Cana-
dian expenditure on detailing and distribution of free
samples for the study drugs, to assess whether other
marketing increased coincidently with US direct to
consumer advertising. We found no evidence of such
changes. Our analysis in the United States used
quarterly data from 50 US Medicaid programmes.
18
Using state level enrolment numbers, we calculated
dispensed prescription rates per 10000 Medicaid
enrolees per quarter.
19 These data provide estimates
up to the end of 2005, when many patients were
transferred to the new Medicare Drug Benefit.
The start month and total spending on US direct to
consumer advertising campaigns came from TNS
Media Intelligence. The dataset tracks advertising
and estimates expenditure across several media,
including television, radio, and print media, and has
been used in previous research on direct to consumer
advertising.
9 We also searched the Vanderbilt Televi-
sion news archive to ascertain when particular drugs
were advertised during major US national news
broadcasts.
20 Finally, we assessed whether manufac-
turers aired television advertising in Canada mention-
ing a brand name by reviewing the databases of
Eloda, an independent company that provides
monitoring and verification services for North
American advertising.
USapprovalandadvertisingdatesandCanadianapprovaldatesforstudydrugs
Drug United States Canada
Generic name Brand name Approval Advertising start DTCA spending to 2006 ($m) Approval
Etanercept Enbrel November 1998 January 2003 $194 December 2000
Mometasone Nasonex October 1997 December 2004 $235 July 1998
Tegaserod Zelnorm July 2002 February 2003 $314 March 2002
DTCA=direct to consumer advertising.
Start dates and US advertising values are from TNS Media Intelligence. Data include spending on network and cable television, magazine, newspaper,
radio, and billboard advertising.
RESEARCH
page 2 of 7 BMJ | ONLINE FIRST | bmj.comStudy drugs
Differences exist between the United States and
Canada in terms of availability and approval dates for
drugs.
21 Consequently, we sought out drugs that were
included in US marketing campaigns started between
January 2003 and December 2005; not advertised on
Canadiantelevisionwithabrandname;andapproved
for use in Canada before US advertising, to allow
estimation of the marginal effect of direct to consumer
advertising on prescribing.
On the basis of these characteristics, we identified
three study drugs. The first eligible drug was
etanercept (Enbrel), a biological agent approved in
Canada for the treatment of symptom refractory
rheumatoid arthritis. Direct to consumer advertising
for etanercept started in January 2003, and US
network news advertising started in March 2003.
20
Thesecondeligibledrugwasmometasone(Nasonex),
an inhaled nasal steroid spray for symptoms of
allergy. Direct to consumer advertising for mometa-
sone started in December 2004, and the Vanderbilt
database showed extensive US news advertising
starting the same month.
20 Thirdly, tegaserod (Zel-
norm)isaserotoninreceptoragonistapprovedforthe
treatment of constipation predominant irritable
bowel syndrome in women. When released, it was
theonlydrugapprovedspecificallyforthisindication
in Canada. Although direct to consumer advertising
began in February 2003, tegaserod’s most influential
and major campaign first aired in August 2003 and
featured memorable written messages such as “I feel
better” on actresses’ stomachs.
6 This later campaign
was considered very successful from a marketing
perspective,andevenwonmajoradvertisingindustry
awards, before the drug was withdrawn in both
Canada and the United States owing to concern
aboutcardiacsideeffects.
622TheVanderbiltdatabase
indicates that US newscast advertising for tegaserod
occurredin1-12September2003andsubsequentlyin
March 2004.
20
Analysis
Weusedregionaldifferencesinexposuretoinvestigate
theimpactofdirecttoconsumeradvertising.AsallUS
advertising was in English, we hypothesised that
changes in prescribing in Canada would be concen-
trated in predominantly English speaking provinces.
Although French speaking Canadians watch a similar
amount of television, they view much less foreign
sourced television, estimated at less than 5% of all
viewing.
16Consequently,weanalysedthedifferencein
prescribing rates between predominantly English
speaking provinces (n=8) and Quebec, where French
is the mother tongue for more than 80% of the
population.
23 Quebec is also attractive as a control as
ithasoneoftheleastrestrictivepublicdrugformularies
in Canada but has comparable universal health
insurance coverage, age, sex, and income profiles to
the other provinces.
2425
We used interrupted time series analysis, one of the
strongest quasi-experimental designs available, to
examinelongitudinalchangesinCanadianprescribing
rates.
26 Firstly, we calculated the difference in the
prescribing rate per 10000 population by subtracting
the rate in French speaking provinces from that in
English speaking provinces. We then fitted time series
modelsto test whethera statistically significantchange
occurredinthelevelortrendofthedifferenceafterthe
start of US advertising or US national network news
advertising, controlling for the pre-direct to consumer
advertising level and trend. This method simulta-
neously controlled for any pre-advertising differences
in the absolute level of prescribing between the
provinces as well as any differences in pre-advertising
temporal trends related to changes in the rates of
prescribing between provinces. We also did a sensitiv-
ity analysis using the ratio of English and French
prescribing rates instead of the difference. The results
and interpretation of this analysis (not shown) were
consistent with those shown below. For drugs that
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Fig 1 | Number of etanercept prescriptions per 10000
population per month in Canadian provinces that are
predominantlyEnglishspeaking(n=8)orFrenchspeaking(n=1).
Vertical line indicates start of US advertising in January 2003.
Differencebetweenratesshownatbottomofchart;fittedtrend
line shows predicted differences from interrupted time series
regression. DTCA=direct to consumer advertising
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Fig 2 | Number of mometasone prescriptions per 10000
population per month in Canadian provinces that are
predominantlyEnglishspeaking(n=8)orFrenchspeaking(n=1).
VerticallineindicatesstartofUSadvertisinginDecember2004.
Differencebetweenratesshownatbottomofchart;fittedtrend
line shows predicted differences from interrupted time series
regression
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advertising in Canada, we did a sensitivity analysis
using data from US Medicaid programmes. We also
did this with an interrupted time series analysis but
without an “unexposed” US control group. Although
this method is uncontrolled compared with the
Canadian analyses, it still controlled for pre-direct to
consumer advertising trends in drug use. We used a
generalised least squares model allowing for a first
order autoregressive correlation between consecutive
months or quarters and excluded the advertising start
month in Canada. We validated our use of this
autocorrelation structure by using likelihood ratio
tests. Moreover, alternative models with no or longer
autocorrelation structures led to results with very
similar estimates and identical interpretations.
RESULTS
Table 1 describes the US advertising campaigns and
Canadian approval dates for the three study drugs. All
three drugs had large direct to consumer advertising
expenditures, ranging from US$194 million to $314
millionduringthestudyperiod.Pre-advertisingtrends
in use for each of the study drugs were generally
comparable between English speaking and French
speaking provinces (figs 1, 2 and 3). We found that US
direct to consumer advertising led to increased
Canadian prescribing rates for only one of the three
drugs, tegaserod.
Etanercept
Figure 1 shows the times series of monthly prescribing
rates of etanercept in Canada, which were very similar
in both language regions. We found that advertising
had no statistically significant impact on the level or
trendofdifferencesinprescribingratebetweenEnglish
speakingandFrenchspeakingprovinces(levelchange
−0.18 prescriptions per 10000 population, 95% con-
fidence interval −0.39 to 0.04, P=0.10; trend change
−0.03 prescriptions per 10000 population per month,
−0.06 to 0.003, P=0.07).
Mometasone
Figure 2 shows the monthly prescribing rates for
mometasoneinEnglishspeakingandFrenchspeaking
Canadian provinces. As with etanercept, we saw no
clinicallyimportantorstatisticallysignificantchangein
the level or trend of differences in prescribing rate
between English speaking and French speaking
provinces (level change −3.61 prescriptions per
10000 population, −10.51 to 3.29, P=0.30; trend
change −0.08 prescriptions per 10000 population per
month, −0.57 to 0.40, P=0.73).
Tegaserod
Incontrasttothefirsttwodrugsdescribed,USdirectto
consumer advertising for tegaserod seemed to have a
strong influence on Canadian prescribing. Figure 3
showsthemonthlyprescribingratesfortegaserod.The
February 2003 campaign, which contained no US
networknewsadvertising,hadnosignificantimpacton
prescribing rates and was incorporated into the pre-
advertising period. In contrast, a level increase of 0.56
prescriptions per 10000 population (0.37 to 0.76,
P<0.001) in the difference in prescribing rate between
English speaking and French speaking provinces
occurredimmediatelyaftertheAugust2003campaign.
We found no statistically significant change in trend
(−0.003 prescriptions per 10000 population per
month, −0.03 to 0.02, P=0.77). Overall, this represents
anestimated42%increaseinthefirstmonthafterdirect
to consumer advertising. However, this difference did
not persist despite continued advertising throughout
the study period. Within two years of direct to
consumer advertising, prescribing rates were again
virtually identical between English speaking and
French speaking regions.
Using the same start date for direct to consumer
advertising, we found a similar increase in Medicaid
prescription rates of tegaserod. Figure 4 showsthat the
pre-advertising upward trend in tegaserod use was
substantially higher in US Medicaid than in Canada.
After national network news direct to consumer
advertising, we saw an increase in the level of
prescribing in the United States; the number of
prescriptions per 10000 enrolees increased by 5.70
(3.65 to 7.75, P<0.001). As in Canada, we found no
statistically significant change in prescribing trends
(−0.62 prescriptions per 10000 enrolees per quarter,
−1.52 to 0.27, P=0.15). Overall, the estimated increase
in prescribing in the first quarter of direct to consumer
advertising was 56% higher than would have been
expected and greater than the 42% increase seen in
Canada.
DISCUSSION
During the past decade, drug manufacturers have
substantiallyincreasedspendingondirecttoconsumer
advertising.
1 To our knowledge, this study is the first
analysis that uses a concurrent control group to
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Fig 3 | Number of tegaserod prescriptions per 10000
population per month in Canadian provinces that are
predominantlyEnglishspeaking(n=8)orFrenchspeaking(n=1).
Vertical lines indicate start of US advertising in February 2003
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specificdrugs.Wefoundthatfortwoofthreedrugsthe
US direct to consumer advertising had no apparent
impactonCanadianprescribingrates,andforonedrug
(tegaserod) we saw a short lived effect. These mixed
findings are surprising, as we included several expen-
siveadvertisingcampaignsthatwerehighlyrecalledby
consumers.
2728 Our empirical results raise important
questions about whether and how prescribing trends
for specific drugs respond to advertising directed at
consumers.Thus,theyhaveimportantimplicationsfor
the ongoing debate about the benefits and harms of
direct to consumer advertising.
Possible explanations
We believe that the differential responses to direct to
consumeradvertisingthatwesawmayberelatedtothe
characteristics of the drugs examined. Although all of
the study drugs are primarily used for relieving
symptoms,theydifferinimportantways.Forexample,
etanercept requires referral to a specialist and intra-
venous administration, making the pathway between
direct to consumer advertising and drug use compli-
cated. Thus, the effect of advertising probably differs
substantially from that of drugs prescribed predomi-
nantly in primary care settings. Furthermore, tega-
serod, unlike the other study drugs, was the only drug
approved for its indication in Canada.
2930 In contrast,
the other drugs studied all had competitors within the
same drug class. In such markets, direct to consumer
advertisingmightprotectagainstdropsinlevelsofuse,
rather than expanding use. Other characteristics, such
as effectiveness, may also be important. A meta-
analysis of short term placebo controlled trials of
tegaserodindicatesthatthenumberneededtotreatfor
one patient to have some improvement in their
gastrointestinal symptoms is about 17, suggesting that
most patients trying tegaserod for the first time were
unlikely to derive symptomatic benefit.
30 This may
explain, in part, why the changes in use for this drug
were short lived.
Ourresultsalsosuggestthatwhendirecttoconsumer
advertisingdoes increaseuse, a dose-responserelation
with the level of exposure to advertising exists. Our
resultsinUSMedicaidprogrammesestimateda larger
increase than in Canada, in both absolute and
percentage terms. Although the immediate change in
use in the United States was larger than in Canada,
assessing the comparative long term effect of advertis-
ing in the United States is difficult, because no
concurrent control group is available. Nevertheless,
the observed US Medicaid prescribing rates returned
tothepre-directtoconsumeradvertisingtrendaround
the same time as in Canada (mid-2005). Furthermore,
use of tegaserod was both higher and growing faster in
Medicaid before direct to consumer advertising,
suggesting that other factors were driving these
differential trends. For example, we cannot rule out
between country differences in physician directed
marketing activities.
31
Strengths and limitations
The major strength of our study is the use of a strong
quasi-experimental design with a comparable and
concurrentcontrolgroup.Moreover,ourstudydesign
controlled for difference in both pre-existing level and
trend and explicitly considered the timing of advertis-
ingcampaigns.Thismethodcontrolsfordifferencesin
characteristics between language regions of Canada
that remained constant or changed predictably over
time, such as culture or patterns of general medical
practice. Indeed, other differences such as variation in
provincial drug reimbursement plans would bias our
results only if they coincidentally changed when the
individual direct to consumer advertising campaigns
started. We could find no evidence that this occurred
for any of the drugs studied. None the less, exclusion
fromprovincialformulariesmightconstraintheeffects
of successful advertising campaigns. However, most
private insurance plans in Canada do not have
formularies and cover most of the population.
32 More-
over, although Ontario and Alberta both excluded
tegaserod from their public drug programmes, the
effectofdirecttoconsumeradvertisingwasapparentin
both provinces (data not shown).
The study has other limitations. Firstly, generalising
beyondthethreedrugsthatmetourinclusioncriteriais
difficult. Secondly, we do not have information on
whether these drugs were subject to disease awareness
advertising by companies that did not mention the
brandname.However,thiswouldbiasourresultsonly
ifitwassimilarlytimed,andwefoundnoindicationfor
mometasoneor etanerceptof increased use coincident
with branded direct to consumer advertising, thus
makingitunlikely.Thirdly,variationindrugcoverage,
theoverallhealthsystem,culture,levelsofexposureto
advertising, or television viewingpatternsmight result
in the effect of direct to consumer advertising differing
between drugs and between countries. However, the
percentage increase in and duration of effect for
tegaserod was similar in both countries. In terms of
drug coverage, more than 60% of Canadians are
covered by generally unrestrictive employer based
privatedrugplans,andlessthan20%oftheseplansuse
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32Although
theCanadianandUShealthsystemsvarysubstantially,
studies indicate similar access to primary care and
willingness of physicians to fulfil patients’ requests for
specific prescription drugs in the two countries.
1533
Overall, the striking initial effect of direct to consumer
advertising on tegaserod prescribing rates provides
evidencethatexposuretoUSadvertisingissufficientto
influence Canadian prescribing.
Implications
Theimplicationsofouranalysisarethreefold.Firstly,it
indicates that illicit cross border exposure to direct to
consumer advertising has the potential to modify drug
use, even where such advertising is technically
prohibited. As advertising over global mediums such
astheinternetincreases,thisphenomenonmaygrowin
importance. Secondly, to our knowledge, these results
are the strongest evidence that direct to consumer
advertisingcanincreaseuseofadrugthatwasremoved
from the market as a result of concerns about safety.
Finally,ourfindingssuggestthattheimpactofdirectto
consumer advertising campaigns is mixed, as they
seem to work for some drugs and not others. If the
overall impact of direct to consumer advertising is
limited or variable, then a substantial portion of
expenditure on such advertising—borne by govern-
ments,insurers,andpatientsintheformofhighercosts
or by companies as reduced profits—may be better
spent elsewhere. Previous commentary may have
overemphasised the impact of direct to consumer
advertising for many individual drugs for which
evidence that it increases use is either weak or non-
existent.
2 Until we better understand how direct to
consumer advertising modifies prescribing for parti-
cular drugs, debates about its positive and negative
consequences will continue to be based on conjecture
rather than strong evidence.
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